Clinical Trial: Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07379827) titled 'Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)' on Jan. 23.

Brief Summary: The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

Study Start Date: Feb. 28

Study Type: OBSERVATIONAL

Condition: Schizophrenia

Intervention: DRUG: Xanomeline and trospium chloride (KarXT)

According to the product label

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bristol-Myers Squibb

Disclaimer: Curated by HT Syndicat...